News - Cardio-vascular


Current filters:


Popular Filters

490 to 514 of 516 results

Johnson & Johnson to take $500-$600 million charge as Cordis drops Cypher heart stents


US health care giant Johnson & Johnson (NYSE: JNJ), which has suffered a steady stream of bad news relating…

Cardio-vascularFinancialJohnson & JohnsonPharmaceutical

US FDA curbs use of high-dose simvastatin, citing increased risk of muscle injury


The US Food and Drug Administration yesterday announced safety label changes for the cholesterol-lowering…

Abbott LaboratoriesCardio-vascularMerck & CoNorth AmericaPharmaceuticalRegulationSimcorSimvastatinZocor

Sanofi presents benefits of semuloparin; Zaltrap improves colorectal cancer survival


French drug major Sanofi (Euronext: SAN) announced results at the American Society of Clinical Oncology…


US FDA says use of ARBs for hypertension does not increase risk of cancer


The US Food and Drug Administration stated yesterday that a group of drugs used to control high blood…

Cardio-vascularNorth AmericaPharmaceuticalRegulation

Health Canada OKs AstraZeneca’s Brilinta and new use for Merck’s Gardasil


Anglo-Swedish drug major AstraZeneca (LSE: AZN) says that Health Canada has approved Brilinta (ticagrelor…

AstraZenecaBrilintaCardio-vascularGardasilMerck & CoNorth AmericaOncologyPharmaceuticalRegulation

Roche joins forces with ChemRar on developing new antithrombotic drug for Russia


Swiss pharmaceutical major Roche (ROG: SIX) and Russian TeaReks company, a subsidiary of ChemRar, Roche's…

Cardio-vascularChemRar Hi-TechEuropeLicensingPharmaceuticalRocheTeaReks

Efficacy and stroke concerns halt trial of Abbott cholesterol drug Niaspan combo


US health care major Abbott Laboratories (NYSE ABT) has halted its AIM-HIGH clinical trial of Niaspan…

Abbott LaboratoriesCardio-vascularNiaspanPharmaceuticalResearchSimvastatin

Synovate Healthcare launches Hyperlipidemia Monitor in Asia-Pacific


Synovate Healthcare, the health care specialist unit of market research firm Synovate, says it has launched…


US Senators accuse Sanofi over lobbying FDA on generic Lovenox


US Senate Finance Committee Chairman Max Baucus (Democrat, Montana) and senior Committee Member Chuck…

Cardio-vascularGenericsLovenoxNorth AmericaPharmaceuticalRegulationSanofi

UK’s NICE recommends naftidrofuryl oxalate for symptoms of peripheral arterial disease


The National Institute for Health and Clinical Excellence (NICE) has today issued final guidance recommending…

Cardio-vascularEuropeMerck SerononaftidrofurylPharmaceuticalPraxilenePricingRegulation

Pfizer’s Inspra shown to reduce AF in Ph IIIb trial


Global drugs behemoth Pfizer (NYSE: PFE) has reported results from a sub-analysis of the Phase IIIb EMPHASIS-HF…


Pfizer and Bristol-Myers get first approval for blood thinner Eliquis, in EU


Following a positive recommendation from its drug advisory body (The Pharma Letter March 21), the European…

Bristol-Myers SquibbCardio-vascularEliquisEuropePfizerPharmaceuticalRegulation

FDA advisory panel backs continued use of Abbott’s Trilipix with statins


The US Food and Drug Administration’s Endocrinologic and Metabolic Drugs Advisory Committee to review…

Abbott LaboratoriesCardio-vascularNorth AmericaPharmaceuticalRegulationTrilipix

Bayer/Ortho-McNeil’s VTE drug Xarelto will earn peak-year sales of $500 million to $1 billion


Following its expected launch in the USA in 2012 for venous thromboembolism (VTE) prophylaxis in medically…

BayerCardio-vascularEliquisJohnson & JohnsonMarkets & MarketingOrtho-McNeilPharmaceuticalXarelto

AstraZeneca achieves three significant milestones for blood thinner Brilique


Anglo-Swedish drug major AstraZeneca (LSE: AZN) yesterday announced three items of news regarding its…


Recordati 1st-qtr 2011 sales up 6.4%, despite generic lercandipine, pivastatin debut


talian drugmaker Recordati SpA (REC: MI) has presented results for the first quarter of 2011 and its…

Cardio-vascularEuropeFinanciallercandipineMarkets & MarketingPharmaceuticalPitavastatinRecordati

Actelion to appeal final jury verdict in Asahi Kasei litigation in US Court


Switzerland-based Actelion (SIX: ATLN) today commented on the verdict issued with regard to Japan’s…

ActelionAsahi KaseiBiotechnologyCardio-vascularCoTherixfasudilLegalLicensing

Novartis gains EU approval for combo drug Rasilamlo to treat high BP


Swiss drug major Novartis (NOVN: VX) says that Rasilamlo, a single-pill combination of aliskiren and…


Karo Bio and Alkem Labs collaborate to develop eprotirome


Sweden’s Karo Bio AB (STO KARO) and Indian drugmaker Alkem Laboratories have entered into a collaboration…

Alkem LaboratoriesAsia-PacificCardio-vasculareprotiromeKaro BioLicensingPharmaceuticalResearchRest of the World

UK NICE gives final yes for Amgen’s Nplate but no for PharmaMar’s Yondelis


There was mixed news this morning from the UK’s drug rationing body the National Institute for Health…


490 to 514 of 516 results

Back to top